Short Interest in Oncolytics Biotech Inc. (NASDAQ:ONCY) Rises By 35.0%

Oncolytics Biotech Inc. (NASDAQ:ONCY) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 3,550,000 shares, a growth of 35.0% from the January 15th total of 2,630,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 3.0 days.

Oncolytics Biotech Price Performance

NASDAQ ONCY traded down $0.00 on Friday, reaching $0.77. The company had a trading volume of 263,905 shares, compared to its average volume of 2,672,717. The firm has a market cap of $61.39 million, a price-to-earnings ratio of -2.84 and a beta of 1.24. Oncolytics Biotech has a fifty-two week low of $0.67 and a fifty-two week high of $1.53. The business has a 50 day moving average of $0.83 and a two-hundred day moving average of $0.96.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th. Leede Financial cut Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research note on Monday, February 3rd.

Institutional Trading of Oncolytics Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the period. National Bank of Canada FI grew its holdings in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after acquiring an additional 42,955 shares during the period. Virtu Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth about $90,000. Vantage Point Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth about $27,000. Finally, International Assets Investment Management LLC grew its holdings in Oncolytics Biotech by 15.0% during the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after acquiring an additional 26,069 shares during the period. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.